Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for cN+ Breast Cancer

  • End date
    Dec 30, 2024
  • participants needed
  • sponsor
    The First Affiliated Hospital with Nanjing Medical University
Updated on 1 July 2022


To explore the feasibility of target biopsy of carbon nanoparticles labelled lymph node after neoadjuvant systemic therapy for cN+ breast cancer, and evaluate whether it can accurately predict axillary lymph node status after neoadjuvant systemic therapy.


Locally advanced breast cancer patients with clinical assessed positive axillary lymph node (cN+) who receive neoadjuvant systemic therapy (NST) will be enrolled in this study. Before NST, one of the suspected lymph nodes will be subjected to ultrasound-guided core needle biopsy (CNB) or fine needle aspiration (FNA), and a locating clip will be placed. Meanwhile, a small amount of Kanarine (Carbon Nanoparticles Suspension Injection) will be injected into or around the cortex of the locating lymph node as well as other positive lymph nodes. All patients will be confirmed to have axillary lymph node metastasis by pathologic or cytologic examination. After NST, FNA will be performed again for the lymph nodes labelled with previous locating clip. During the operation, the clip labelled lymph nodes were identified with carbon and sent to pathology separately. Meanwhile, the remaining carbon labelled lymph nodes were also separately examined. Axillary lymph node dissection will be performed in all patients. The detection rate of labelled lymph node will be record, and the pathological results of re-FNA of labelled lymph nodes will be compared with postoperative pathological results. Meanwhile, we will also analysis whether carbon labelled lymph node biopsy could predict the overall status of axillary lymph nodes after NST.

Condition Location and Biopsy of Axillary Lymph Nodes
Treatment Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
Clinical Study IdentifierNCT04482803
SponsorThe First Affiliated Hospital with Nanjing Medical University
Last Modified on1 July 2022


Yes No Not Sure

Inclusion Criteria

Female breast cancer patients who received neoadjuvant systemic chemotherapy, aged 18-70 years old, with clinically assessed positive lymph node, and the expected survival period is greater than 12 months
No previous radiotherapy and chemotherapy
No history of serious systemic disease
White blood cell count> 3.5 × 10 ^ 9 / L, neutrophil count> 1.8 × 10 ^ 9 / L, platelet count> 100 × 10 ^ 9 / L, hemoglobin> 9 g / dl
ALT and AST <1.5 times the upper limit of normal value, alkaline phosphatase <2.5 times the upper limit of normal value, and total bilirubin <1.5 times the upper limit of normal value
Serum muscle plasma <1.5 times the upper limit of normal value
No abnormal blood coagulation
Women of childbearing age had a negative serum or urine pregnancy test before the start of treatment and agreed to contraception during treatment
Cardiac function: two-dimensional echocardiography examination LVEF ≥ 55%
Sign informed consent
Exclusion critia
Received systemic or local treatment for tumors, including chemotherapy, radiotherapy and endocrine therapy
A history of malignant tumors within 5 years (except curable skin basal cell carcinoma and cervical carcinoma in situ)
The patient has been enrolled in other clinical trials or used other study drugs 30 days before enrollment in this study
Accompanied by uncontrolled lung disease, severe infection, active gastrointestinal ulcer need treatment, coagulopathy, severe uncontrolled diabetes, connective tissue disease or bone marrow function suppression and other diseases, can not tolerate chemotherapy related treatments
Two-dimensional echocardiography detection LVEF <55%
Severe cardiovascular and cerebrovascular diseases within the first 6 months of randomization (eg unstable angina, chronic heart failure, uncontrollable hypertension> 150/90 mmHg, myocardial infarction or cerebrovascular accident)
NCI peripheral neurotoxicity grade ≥2
Those taking glucocorticoids
Known hypersensitivity to anthracyclines, cyclophosphamide, taxanes, trastuzumab or pertuzumab
Refuse contraception during treatment and within 8 weeks after completion of treatment for women of childbearing age
Pregnant and lactating women
After joining the test, a pregnancy test (+) before using the drug
There are mental illness, cognitive impairment, unable to understand the test plan and side effects, unable to complete the test plan and follow-up workers (systematic evaluation is required before the trial is enrolled)
No personal freedom and independent civil capacity
The investigator determined that the patient could not obtain long-term follow-up data (due to unavailability or serious concomitant diseases)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note